EUVIMEDEUVIMED entdecken
Crossref

Anti‐amyloid antibodies in Europe: Where are we now?

Danica Juricic Nahal, Petar Mas, Ivana Cegec iD, Margareta Bego, Iva Klarica Domjanovic

British Journal of Clinical Pharmacology · 2026-06 · 92 (6) · 1533-1535

DOI: 10.1002/bcp.70526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 11.03.2026. Verfasst von Danica Juricic Nahal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department for Safety and Efficacy Assessment, Agency for Medicinal Products and Medical Devices of Croatia, Zagreb, Croatia. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department for Safety and Efficacy Assessment, Agency for Medicinal Products and Medical Devices of Croatia, Zagreb, Croatia.
  • University Hospital Centre Zagreb, Zagreb, Croatia.

ORCID-Profile: Ivana Cegec

Zitieren

APA

Juricic Nahal, D., Mas, P., Cegec, I., Bego, M., & Domjanovic, I. K. (2026). Anti‐amyloid antibodies in Europe: Where are we now?. British Journal of Clinical Pharmacology, 92(6), 1533-1535. https://doi.org/10.1002/bcp.70526

Vancouver

Juricic Nahal D, Mas P, Cegec I, Bego M, Domjanovic IK. Anti‐amyloid antibodies in Europe: Where are we now?. British Journal of Clinical Pharmacology. 2026;92(6):1533-1535. doi:10.1002/bcp.70526

BibTeX
@article{JuricicNahal2026,
  author = {Juricic Nahal, Danica and Mas, Petar and Cegec, Ivana and Bego, Margareta and Domjanovic, Iva Klarica},
  title = {Anti‐amyloid antibodies in Europe: Where are we now?},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {6},
  pages = {1533--1535},
  doi = {10.1002/bcp.70526}
}
Kostenlos starten →